(Q58322637)

https://api.crossref.org/works/10.1002%2FHEP.1840360727

Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

High Compliance with a Hepatitis B Virus Vaccination Program among Intravenous Drug Users

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

Provider assessment of adherence to HIV antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992 to 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

Case-reporting of acute hepatitis B and C among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

Correlates of hepatitis C virus infections among injection drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Public health and changes in illicit drug prices

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Nonadherence in tuberculosis treatment: predictors and consequences in New York City.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Helping the urban poor stay with antiretroviral HIV drug therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

A cohort study of drug users' compliance with zidovudine treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Compliance with treatment regimens in chronic asymptomatic diseases

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Accuracy of doctors' estimates and patients' statements on adherence to a drug regimen

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Compliance with cyclosporine in adolescent renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Treatment of hepatitis C infection in injection drug users

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Treating hepatitis C in methadone maintenance patients: an interim analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Medical care for injection-drug users with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

HIV disease in the intravenous drug user: role of the primary care physician

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Harm reduction: a public health response to the AIDS epidemic among injecting drug users

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Harm reduction: concepts and practice. A policy discussion paper.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Treating drug problems

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Drug abuse treatment as an HIV prevention strategy: a review

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Syringe prescription to prevent HIV infection in Rhode Island: a case study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Physician prescribing of sterile injection equipment to prevent HIV infection: time for action

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Syringe and needle exchange as HIV/AIDS prevention for injection drug users

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

The effect of syringe exchange use on high-risk injection drug users: a cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Risk factors among IDUs who give injections to or receive injections from other drug users

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Pharmacists' attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Community-based programs for safe disposal of used needles and syringes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

The natural history of hepatitis C virus infection: host, viral, and environmental factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360727

7 January 2021